Published in Am J Nucl Med Mol Imaging on December 15, 2013
Positron emission tomography image-guided drug delivery: current status and future perspectives. Mol Pharm (2014) 0.88
Medical management of metastatic medullary thyroid cancer. Cancer (2014) 0.88
DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging (2015) 0.78
Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity. Arch Immunol Ther Exp (Warsz) (2014) 0.75
Incidentally Detected Thyroid Follicular Neoplasm on Somatostatin Receptor Imaging and Post-therapy Scan. Indian J Nucl Med (2017) 0.75
Nodular Thyroid Disease and Thyroid Cancer in the Era of Precision Medicine. Eur Thyroid J (2017) 0.75
DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet (2000) 6.57
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab (2006) 5.78
DNA damage-induced cell death by apoptosis. Trends Mol Med (2006) 4.67
Thyroid carcinoma. Lancet (2003) 4.08
Processing of generator-produced 68Ga for medical application. J Nucl Med (2007) 2.75
Current management of medullary thyroid cancer. Oncologist (2008) 1.80
New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab (2008) 1.76
New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol (2007) 1.74
An overview of the management of papillary and follicular thyroid carcinoma. Thyroid (1999) 1.72
Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab (2005) 1.68
Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg (1996) 1.65
Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab (2005) 1.63
Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging (2010) 1.39
Hürthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol (2001) 1.37
Measurement of prompt DNA double-strand breaks in mammalian cells without including heat-labile sites: results for cells deficient in nonhomologous end joining. Radiat Res (2003) 1.30
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med (2011) 1.27
Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab (1999) 1.19
Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab (1997) 1.16
Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res (2007) 1.15
Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys (2008) 1.12
Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging (2010) 1.11
[(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer (2009) 1.08
111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med (2000) 1.05
Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.05
Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2012) 1.03
Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab (2001) 1.00
99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer. Eur J Surg Oncol (2007) 0.90
Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res (2009) 0.90
DNA repair patch-mediated double strand DNA break formation in human cells. J Biol Chem (2000) 0.90
Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med (1996) 0.89
Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab (2005) 0.88
The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC. Recent Results Cancer Res (2013) 0.88
Hürthle cell neoplasms of the thyroid gland: reassessment of functional capacity. Thyroid (1994) 0.85
Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med (2012) 0.85
Radiation biology and treatment options in radiation oncology. Cancer Res (1999) 0.84
Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors. Recent Results Cancer Res (2013) 0.83
Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies. Thyroid (2009) 0.83
(68)Ga-DotaTATE PET-CT followed by Peptide Receptor Radiotherapy in combination with capecitabine in two patients with Merkel Cell Carcinoma. Int J Clin Exp Med (2012) 0.83
Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology. Ann Nucl Med (2012) 0.82
Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma. Semin Nucl Med (2011) 0.82
Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation. Nucl Med Biol (2008) 0.80
Unmethylated thyroglobulin promoter may be repressed by methylation of flanking DNA sequences. Biochem J (1994) 0.78
A patient with medullary thyroid carcinoma and right ventricular cardiac metastasis treated by (90)Y-Dotatoc. Hell J Nucl Med (2009) 0.77